Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolanta in Recurrent Ovarian Cancer
NCT02534922Phase 1Unknown
- Sponsor
- Oncolix, Inc.
- Start
- Feb 2016
- Primary completion
- Feb 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Prolanta in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Oncolix, Inc. Primary endpoints: Number of Subjects with Treatment Related Adverse Events at 90 days and Optimal Phase II Dose. Status: unknown.
02
Drugs
Prolanta
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02534922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534922.